Challenges of Life Sciences Partnerships

The necessity of the Biotech partnership is more important than ever.  Due to the increasing cost of commercializing a compound, coupled with the weak capital markets, many CEOs are exploring partnerships earlier in the life cycle of their company to meet capital demands.  This increased focus on partnership, coupled with Big Pharma’s depleted pipeline, causes increased focus on partnership terms and the need for multiple compounds in the private company’s pipeline.  This current market dynamic specifically heightens the CEOs fear of “selling” the company through a partnership that is too restrictive and potentially exposing core intellectual property to competitors.

Life Sciences CEOs are invited to attend.  Space is limited. No cost for Alliance members.

If you would like to attend this event, please fill out the form below: